← Eichor
Condition: Relapsed Or Refractory Cd19 B Cell Lymphoma Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Relapsed Or Refractory Cd19 B Cell Lymphoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)
Phase 2/Phase 3 · 12 location(s) · Merck Sharp & Dohme LLC · NCT07570173CAR2219 CAR-T Cells for the Treatment of R/R B Cell Leukemia and Lymphoma
Phase 1/Phase 2 · 1 location(s) · Affiliated Hospital to Academy of Military Medical Sciences · NCT06834529An Early Clinical Study Evaluating the Safety and Efficacy of AcNK-Sup003 Cell Injection in the Treatment of Relapsed or
EARLY_Phase 1 · 1 location(s) · Union Hospital, Tongji Medical College, Huazhong University · NCT06693973CD19-targeted CAR T Cells for Relapsed or Refractory (R/R) Large B-cell Lymphoma
Phase 2 · 1 location(s) · Shanghai Ming Ju Biotechnology Co., Ltd. · NCT06479356A Study of mRNA Encoding CD19/CD3 T Cell Engager (ABO2203) in Patients With Relapsed or Refractory B-cell Non-Hodgkin Ly
Phase 1 · 1 location(s) · Ruijin Hospital · NCT07072169A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic
Phase 1 · 8 location(s) · Autolus Limited · NCT06173518Safety and Efficacy of PRG-2302 for Refractory or Relapsed B-cell Acute Lymphoblastic Leukemia Disease.
EARLY_Phase 1 · 1 location(s) · Tan Jie · NCT06659653Study of Cord Blood-derived CAR NK Cells Targeting CD19/CD70 in Refractory/Relapsed B-cell Non-Hodgkin Lymphoma
Phase 1/Phase 2 · 1 location(s) · Aibin Liang，MD，Ph.D. · NCT05842707Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell Lymphoma
Phase 1/Phase 2 · 5 location(s) · Pell Bio-Med Technology Co., Ltd. · NCT05326243A Study of Murine CD19 CAR-T Therapy for Patients With Relapsed or Refractory CD19+ B-cell Hematological Malignancies
EARLY_Phase 1 · 1 location(s) · Zhejiang University · NCT04532281Safety and Efficacy of CAR T Cell Therapy in Patients with R/r B-ALL
Phase 1/Phase 2 · 1 location(s) · Kara Yakhteh Tajhiz Azma Company · NCT06635330Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL Patients
Phase 1 · 1 location(s) · University of Colorado, Denver · NCT05098613UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL
Phase 1/Phase 2 · 1 location(s) · University of Colorado, Denver · NCT04544592CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies
EARLY_Phase 1 · 1 location(s) · Zhejiang University · NCT04603872CAR-T Cell Therapy for ALL
EARLY_Phase 1 · 1 location(s) · Dr. Zaineb Akram · NCT07695012Treatment of Relapsed or Refractory B-cell Lymphoma With Chimeric Antigen Receptor (CAR) T-cell Therapy Produced by a Ne
Phase 1/Phase 2 · 8 location(s) · Instituto de Investigación Biomédica de Salamanca · NCT06378190DALY II Japan/MB-CART2019.1 for DLBCL
Phase 2 · 5 location(s) · Miltenyi Biomedicine GmbH · NCT07288879Clinical Study of U01（ssCART-19） in Patients With B-Cell Lymphoma
Phase 1 · 1 location(s) · Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd · NCT07093073A Study of 19-28z/IL-18 in People With Acute Lymphoblastic Leukemia (ALL)
Phase 1 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT06287528Study of Efficacy and Safety of CRC01 in Adult Large B-cell Lymphoma and B-cell Acute Lymphoblastic Leukemia Patients
Phase 1/Phase 2 · 2 location(s) · Curocell Inc. · NCT04836507Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL
Phase 1/Phase 2 · 1 location(s) · Medical University of South Carolina · NCT05702853Co-administration of CART22-65s and huCART19 for B-ALL
Phase 1/Phase 2 · 1 location(s) · Stephan Grupp MD PhD · NCT05674175DALY II USA/ MB-CART2019.1 for DLBCL
Phase 2 · 32 location(s) · Miltenyi Biomedicine GmbH · NCT04792489Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies
Phase 1/Phase 2 · 1 location(s) · Beijing Biotech · NCT07523555Allogenic CD19-targeting CAR-γδT Cell Therapy in R/R NHL
Phase 1/Phase 2 · 2 location(s) · Chinese PLA General Hospital · NCT05554939The Safety and Efficacy of BRL-201 in the Treatment of r/r B Lymphocyte Non-Hodgkin Lymphoma
Phase 1 · 3 location(s) · Bioray Laboratories · NCT05741359Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma
Phase 1/Phase 2 · 26 location(s) · Kite, A Gilead Company · NCT04989803A Clinical Study of Allogeneic CD19/BCMA CAR-T Cells for the Treatment of R/R B-cell Malignant Tumors
EARLY_Phase 1 · 1 location(s) · YANRU WANG · NCT06976437Allogeneic CARCIK-CD19 in Adults/Pediatric B-cell NHL or Chronic Lymphocytic Leukemia
Phase 1/Phase 2 · 1 location(s) · Fondazione Matilde Tettamanti Menotti De Marchi Onlus · NCT05869279CAR-T Followed by Bispecific Antibodies
Phase 2 · 2 location(s) · Abramson Cancer Center at Penn Medicine · NCT04889716
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.